Answers are grounded in this paper and cite their sources.
CD19-targeted chimeric antigen receptor (CAR)-T cell therapy has shown high potential for treating B-cell hematological malignancies and has been approved by the US FDA. However, CAR-T cell therapy for T-cell hematologic malignancies poses feasibility challenges, including the difficulty of obtaining sufficient healthy cells from patients, CAR-T cell fratricide, and the risk of immunodeficiency. In this review, we discuss bottlenecks and possible solutions in CAR-T cell therapy for T-cell acute lymphoblastic leukemias, as well as future directions in this field.
No takes yet. Share an insight, caveat, or question.
Shan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: